Official UK procurement notice
Supply and Installation of PhysioMimix OOC Multi-OrganFull System
Authority: THE UNIVERSITY OF BIRMINGHAM (Education)
What is being bought
Published requirement descriptionThe PhysioMimix® Multi-Tissue System is particularly well suited for use in a core facility (Birmingham Tissue Analytics), where flexibility and broad applicability are key. Its modular design allows different organ models to be easily configured and reconfigured to suit a range of project needs-from single-organ toxicity studies to multi-organ interaction and disease modelling. With standardized protocols and user-friendly operation, it supports consistent, high-quality data generation across diverse applications, making it an efficient and adaptable platform for multiple research groups and project types.
The lotProcurement structure
single lot · no lot value publishedLot #1Awarded
Procedure terms & legal framework
From the official record- Procedure method
- Direct award
- Legal basis
- UKPGA · 2023/54 Procurement Act 2023
- Notice status
- Awarded without competition
- Procurement threshold
- Unspecified in notice
- Regulatory regime
- Standard
- Commercial structure
- Stand-alone contract (no framework)
- Competition type
- Direct award (no call for competition)
- GPA / WTO covered
- Unspecified in notice
- Recurring procurement
- Unspecified in notice
- First published
- 24 Jun 2025, 09:10 BST
- Last source update
- 24 Jun 2025, 09:10 BST
- Authority reference
SC13833/25- FTS notice number
2025/S 000-034566- Latest notice
- Transparency notice (UK5)
- Delivery area
- Official registry OCID
ocds-h6vhtk-05522dFind a Tender
- Why no open competition
- Urgency
- Published justification
The PhysioMimix® Multi-Tissue System offers a highly advanced, solution for modelling systemic human biology in vitro. By enabling the dynamic co-culture of multiple organ models-such as liver, gut, and lung-within a single, perfused microphysiological system, it provides a unique opportunity to assess inter-organ interactions, drug metabolism, distribution, and toxicity in a more integrated and human-relevant context. Product features include an open-well consumable plate design, media is pneumatically pumped recirculated through microfluidics within these plates to perfuse tissue cultures. Modular PhysioMimix® hardware consists of a Controller, Docking Station(s), and MPS driver(s), and consumable plates controlled via proprietary software. This is underpinned by patents exclusively licensed from MIT to CN Bio.
This system is particularly valuable for studying drug pharmacokinetics and pharmacodynamics (PK/PD) across tissues, evaluating how metabolites formed in one organ (e.g., liver) influence the function or toxicity of others. Such capability is crucial for understanding off-target effects, bioactivation pathways, and multi-organ toxicity that are often missed in single-organ or animal models.
Notice history
2 events · 1 release on Find a Tender · since 24 Jun 2025- Transparency notice published24 Jun 2025, 09:10 BSTUK5
- Contract signature expected24 Jun 2025, 23:59 BSTscheduled
Commercial outcome & contract awards
Published awards, contracts and bid statistics, not a forecast| Awarded to | Value | Date | Status |
|---|---|---|---|
| CN Bio Innovations Limited2 Jul 2025 – 28 May 2026 | £298,045 | — | Standstill |
Contracting authority & participating public bodies
Bidders & participating suppliers
1 commercial party on the notice- CN Bio Innovations LimitedAwarded supplier
Official documents & specifications (1)
Official links; attachments are not copiedNotices published for this procedure
- Transparency notice Transparency notice on Find a Tender